Elicio

Elicio's AMPLIFY-7P: Including PRODIGE 24 And Extending The Control DFS Corridor Still Favors Vaccine Efficacy (Monte Carlo Simulation…

Including PRODIGE 24 in the control arm DFS estimate, extended control arm DFS corridor, and March readout reaffirmation conditioning still favors…

4 hrs ago • Chaotropy

Two Delayed Cancer Vaccine Readouts: Why I Am More Optimistic About AMPLIFY-7P Than REGAL

AMPLIFY-7P and REGAL are both delayed. Why the scientific case for ELI-002 in PDAC may rest on firmer ground than GPS in CR2 AML.

Mar 16 • Chaotropy

Johns Hopkins mKRAS Vaccine Trial Strengthens The Case For Elicio's ELI-002

A Hopkins mKRAS vaccine trial shows KRAS peptides generate durable T cell immunity correlating with survival, consistent with Elicio's AMPLIFY-201.

Mar 9 • Chaotropy

Monte Carlo Simulation Of Elicio's Phase II AMPLIFY-7P Study Favors Vaccine Efficacy

Monte Carlo simulation maps AMPLIFY-7P's readout delay onto control-arm survival and vaccine HR. Efficacy scenarios fit 2-3x better.

Mar 1 • Chaotropy

Elicio’s Therapeutic Vaccine For Pancreatic Cancer: A Revolution Hidden In Plain Sight?

Elicio's mKRAS vaccine achieved 84% T-cell response in pancreatic cancer Phase 1. Phase 2 readout in H1 2026 could redefine adjuvant therapy.

Jan 25 • Chaotropy

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts